By indication / Bone metastases and bone lesions
Bone metastases and bone lesions
3 imaging agents and 11 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [18F]NaF | F-18 | Approved | 10 |
| [68Ga]Ga-BPAMD paired with [161Tb]Tb-BPAMD | Ga-68 | Clinical research | 5 |
| [89Zr]Zr-DFO-girentuximab | Zr-89 | Clinical research | 1 |
Therapy
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [177Lu]Lu-PSMA-617 paired with [68Ga]Ga-PSMA-11 | Lu-177 | Approved | 35 |
| [153Sm]Sm-EDTMP | Sm-153 | Approved | 3 |
| [223Ra]Ra-RaCl2 | Ra-223 | Approved | 3 |
| [177Lu]Lu-BPAMD paired with [68Ga]Ga-BPAMD | Lu-177 | Clinical research | 2 |
| [177Lu]Lu-FAP-2286 paired with [68Ga]Ga-FAP-2286 | Lu-177 | Clinical research | 1 |
| [188Re]Re-188-HEDP | Re-188 | Clinical research | 1 |
| [161Tb]Tb-BPAMD paired with [68Ga]Ga-BPAMD | Tb-161 | — | 1 |
| [225Ac]Ac-DOTAZOL | Ac-225 | Preclinical | 1 |
| [153Sm]Sm-BPAMD paired with [68Ga]Ga-BPAMD | Sm-153 | Preclinical | |
| [177Lu]Lu-vipivotide | Lu-177 | Approved | |
| [211At]At-astatobenzamide-N-3-hydroxypropylidene-3 | At-211 | Preclinical |
Other entries
| Agent | Isotope | Stage | Runs |
|---|---|---|---|
| [153Sm]Sm-DOTMP | Sm-153 | — | |
| [161Tb]Tb-DOTA-IBA | Tb-161 | Clinical research | |
| [131I]I-Risedronate | I-131 | — | |
| [188Re]Re-IBA | Re-188 | — | |
| [89Sr]Sr | Sr-89 | — | |
| [166Ho]Ho-TRITP | Ho-166 | Preclinical |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region - tell us what you need.
Get in touch